Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Sanofi gets grant for rsv polypeptides for antibody elicitation against respiratory syncytial virus
Sanofi's patent includes antigenic respiratory syncytial virus (RSV) polypeptides designed to elicit antibodies against RSV. The claim specifies a glycosylated...
SAR-447537 by Sanofi for Emphysema: Likelihood of Approval
SAR-447537 is under clinical development by Sanofi and currently in Phase II for Emphysema. According to GlobalData, Phase II drugs...
Frexalimab by Sanofi for Systemic Lupus Erythematosus: Likelihood of Approval
Frexalimab is under clinical development by Sanofi and currently in Phase II for Systemic Lupus Erythematosus. According to GlobalData, Phase...
Amlitelimab by Sanofi for Alopecia Areata: Likelihood of Approval
Amlitelimab is under clinical development by Sanofi and currently in Phase II for Alopecia Areata. According to GlobalData, Phase II...
Fitusiran by Sanofi for Hemophilia A (Factor VIII Deficiency): Likelihood of Approval
Fitusiran is under clinical development by Sanofi and currently in Pre-Registration for Hemophilia A (Factor VIII Deficiency). According to GlobalData,...
Fitusiran by Sanofi for Hemophilia B (Factor IX Deficiency): Likelihood of Approval
Fitusiran is under clinical development by Sanofi and currently in Pre-Registration for Hemophilia B (Factor IX Deficiency). According to GlobalData,...
PRV-3279 by Sanofi for Systemic Lupus Erythematosus: Likelihood of Approval
PRV-3279 is under clinical development by Sanofi and currently in Phase II for Systemic Lupus Erythematosus. According to GlobalData, Phase...
Frexalimab by Sanofi for Relapsing Multiple Sclerosis (RMS): Likelihood of Approval
Frexalimab is under clinical development by Sanofi and currently in Phase III for Relapsing Multiple Sclerosis (RMS). According to GlobalData,...
Venglustat malate by Sanofi for Gaucher Disease Type III: Likelihood of Approval
Venglustat malate is under clinical development by Sanofi and currently in Phase III for Gaucher Disease Type III. According to...
SAR-441566 by Sanofi for Rheumatoid Arthritis: Likelihood of Approval
SAR-441566 is under clinical development by Sanofi and currently in Phase II for Rheumatoid Arthritis. According to GlobalData, Phase II...
Isatuximab by Sanofi for Natural Killer Cell Lymphomas: Likelihood of Approval
Isatuximab is under clinical development by Sanofi and currently in Phase II for Natural Killer Cell Lymphomas. According to GlobalData,...
Isatuximab by Sanofi for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
Isatuximab is under clinical development by Sanofi and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)....
Pegenzileukin by Sanofi for Oropharyngeal Cancer: Likelihood of Approval
Pegenzileukin is under clinical development by Sanofi and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase II...
SAR-442501 by Sanofi for Achondroplasia: Likelihood of Approval
SAR-442501 is under clinical development by Sanofi and currently in Phase I for Achondroplasia. According to GlobalData, Phase I drugs...
Fresolimumab by Sanofi for Non-Small Cell Lung Cancer: Likelihood of Approval
Fresolimumab is under clinical development by Sanofi and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Sanofi's Itepekimab?
Itepekimab is a monoclonal antibody commercialized by Sanofi, with a leading Phase III program in Chronic Obstructive Pulmonary Disease (COPD)....
Risk adjusted net present value: What is the current valuation of Sanofi's Rilzabrutinib?
Rilzabrutinib is a small molecule commercialized by Sanofi, with a leading Phase III program in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic...
Risk adjusted net present value: What is the current valuation of Sanofi's Tolebrutinib?
Tolebrutinib is a small molecule commercialized by Sanofi, with a leading Phase III program in Primary Progressive Multiple Sclerosis (PPMS)....
Risk adjusted net present value: What is the current valuation of Sanofi's Venglustat malate?
Venglustat malate is a small molecule commercialized by Sanofi, with a leading Phase III program in Fabry Disease. According to...
Sanofi files patent for recombinant antibodies for inhibiting b7-h4 in disease treatment
Sanofi has filed a patent for recombinant antibodies and fusion proteins that can bind to and inhibit B7-H4, a protein...